ATP depletion in anthrax edema toxin pathogenesis
PLOS Pathogens · 2025
DOI: 10.1371/journal.ppat.1013017 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, 2025. Verfasst von Jie Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Aging Institute of University of Pittsburgh and University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States of America. Hauptthemen laut MEDLINE: Bacterial Toxins, Antigens, Bacterial, Adenosine Triphosphate, Bacillus anthracis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: NIAID NIH HHS, Aging Institute of University of Pittsburgh School of Medicine, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Anthrax lethal toxin (LT) and edema toxin (ET) are two of the major virulence factors of Bacillus anthracis , the causative pathogen of anthrax disease. While the roles of LT in anthrax pathogenesis have been extensively studied, the pathogenic mechanism of ET remains poorly understood. ET is a calmodulin-dependent adenylate cyclase that elevates intracellular cAMP by converting ATP to cAMP. Thus, it was postulated that the ET-induced in vivo toxicity is mediated by certain cAMP-dependent events. However, mechanisms linking cAMP elevation and ET-induced damage have not been established. Cholera toxin is another bacterial toxin that increases cAMP. This toxin is known to cause severe intestinal fluid secretion and dehydration by cAMP-mediated activation of protein kinase A (PKA), which in turn activates cystic fibrosis transmembrane conductance regulator (CFTR). The cAMP-activated PKA phosphorylation of CFTR on the surface of intestinal epithelial cells leads to an efflux of chloride ions accompanied by secretion of H 2 O into the intestinal lumen, causing rapid fluid loss, severe diarrhea and dehydration. Due to similar in vivo effects, it was generally believed that ET and cholera toxin would exhibit a similar pathogenic mechanism. Surprisingly, in this work, we found that cAMP-mediated PKA/CFTR activation is not essential for ET to exert its in vivo toxicity. Instead, our data suggest that ET-induced ATP depletion may play an important role in the toxin’s pathogenesis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Aging Institute of University of Pittsburgh and University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States of America.
- Division of Cardiology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.
- PhD program, Department of Environmental and Occupational Health, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, United States of America.
- Microbial Pathogenesis Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
- Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.
ORCID-Profile: Shihui Liu
Förderung
- NIAID NIH HHS
- Aging Institute of University of Pittsburgh School of Medicine
- National Institute of Allergy and Infectious Diseases
- NIAID
Zitieren
APA
Liu, J., Cao, Q., Ewing, M., Zuo, Z., Kennerdell, J. R., Finkel, T., Leppla, S. H., & Liu, S. (2025). ATP depletion in anthrax edema toxin pathogenesis. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1013017
Vancouver
Liu J, Cao Q, Ewing M, Zuo Z, Kennerdell JR, Finkel T, et al. ATP depletion in anthrax edema toxin pathogenesis. PLOS Pathogens. 2025. doi:10.1371/journal.ppat.1013017
BibTeX
@article{Liu2025,
author = {Liu, Jie and Cao, Qing and Ewing, Michael and Zuo, Zehua and Kennerdell, Jason R and Finkel, Toren and Leppla, Stephen H and Liu, Shihui},
title = {ATP depletion in anthrax edema toxin pathogenesis},
journal = {PLOS Pathogens},
year = {2025},
doi = {10.1371/journal.ppat.1013017}
}
EUVIMED